Opinion: Should the FDA speed up or slow down approval of new cancer drugs?
When making decisions about the required level of evidence to approve cancer drugs, the FDA should continue taking a more patient-centered approach.
Earlier this month, the Food and Drug Administration announced the creation of Project Facilitate. This pilot program facilitates access to innovative treatments for cancer that have not yet been approved by individuals who aren’t able to enroll in clinical trials. This move suggests that the FDA finds the approval process for cancer drugs to be too slow.
At the same time, some experts want the FDA to slow down the approval process for cancer treatments. A recent article in argued that cancer drugs are receiving accelerated approval without sufficient evidence proving they are safe and
